Document Detail

Impact of biomarker usage on oncology drug development.
MedLine Citation:
PMID:  23057528     Owner:  NLM     Status:  Publisher    
What is known and Objective:  The increasing cost of drug research and development and the decreasing number of new drugs being launched are serious issues for pharmaceutical companies. Biomarkers for predicting drug effectiveness are regarded as useful tools for combating these trends. However, the extent to which these biomarkers actually help in improving drug development is unclear. Here, we investigated the efficiency of biomarker usage in oncology drug development by focusing on stratification markers. Methods:  Anti-tumour agents for which clinical studies were initiated between 1998 and 2009 were identified using commercially available data sources, and clinical trials registered in were examined to identify the use of stratification marker. Phase transition probability for each clinical phase was calculated and analysed along with various other factors that may affect the efficiency of the development process. Results and Discussion:  Of 908 anti-tumour agents identified, 121 (13·3%) utilized stratification markers in their clinical studies. Phase I, II and III transition probabilities for all agents were 76·4%, 50·8% and 58·5%, respectively. Corresponding Phase I, II and III transition probabilities of agents developed with stratification markers of 90·4%, 69·0% and 85·0%, respectively, were significantly higher than those for agents without stratification markers. Orphan designation positively affected phase transition probabilities of agents without stratification markers in all phases, while it did not affect transition probabilities of agents with stratification markers, except for Phase II. This shows that stratification markers help improve the probability of success in the development of agents without orphan designation. What is new and Conclusion:  Stratification markers contribute to improving the efficiency of development of anti-cancer drugs. The majority of non-orphan drugs are still being developed without stratification markers. Finding reliable stratification markers for all drugs should improve the success rates in drug development.
K Hayashi; S Masuda; H Kimura
Related Documents :
23525058 - Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.
8122698 - Pharmacokinetics and interactions of antiepileptic drugs.
10929928 - Newer anticonvulsants: comparative review of drug interactions and adverse effects.
1823508 - Critical comment on the determination of plasma level of antiepileptic drugs in the tre...
12743638 - Pharmacodynamics of drug-induced weight gain.
16096128 - Exploring the relationship between homelessness and risk factors for heroin-related dea...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-11
Journal Detail:
Title:  Journal of clinical pharmacy and therapeutics     Volume:  -     ISSN:  1365-2710     ISO Abbreviation:  J Clin Pharm Ther     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8704308     Medline TA:  J Clin Pharm Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Pharmaco-Business Innovation Laboratory, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo Office of Pharmaceutical Industry Research, Japan Pharmaceutical Manufacturers Association, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Development of Mechanism-based Structural Alerts for Respiratory Sensitisation Hazard Identification...
Next Document:  Peri-implant tissue reactions to immediate nonocclusal loaded implants with different collar design:...